Scott H Donaldson

List of Publications by Year
in descending order

78 papers	6,773 citations	101543 36 h-index	71685 76 g-index
80 all docs	80 docs citations	80 times ranked	5412 citing authors

#	Article	IF	Citations
1	Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study. Journal of Cystic Fibrosis, 2022, 21, 143-145.	0.7	12
2	Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 529-539.	5.6	147
3	AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 684-690.	0.7	3
4	Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer. Journal of Visualized Experiments, 2022, , .	0.3	1
5	Effect of airway clearance therapies on mucociliary clearance in adults with cystic fibrosis: A randomized controlled trial. PLoS ONE, 2022, 17, e0268622.	2.5	2
6	Current state of CFTR modulators for treatment of Cystic Fibrosis. Current Opinion in Pharmacology, 2022, 65, 102239.	3.5	19
7	Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial. Annals of the American Thoracic Society, 2021, 18, 75-83.	3.2	32
8	Comparison of single breath hyperpolarized ¹²⁹Xe MRI with dynamic ¹⁹F MRI in cystic fibrosis lung disease. Magnetic Resonance in Medicine, 2021, 85, 1028-1038.	3.0	12
9	PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. Journal of Cystic Fibrosis, 2021, 20, 205-212.	0.7	39
10	Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design. Annals of the American Thoracic Society, 2021, 18, 1397-1405.	3.2	38
11	Development of an Advance Care Planning Protocol in a Cystic Fibrosis Outpatient Clinic. Journal of Palliative Medicine, 2021, 24, 1383-1386.	1.1	0
12	Inhibition of ATP hydrolysis restores airway surface liquid production in cystic fibrosis airway epithelia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L356-L365.	2.9	10
13	Airway Mucus Hyperconcentration in Nonâ€“Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 661-670.	5.6	64
14	Effect of hypertonic saline on mucociliary clearance and clinical outcomes in chronic bronchitis. ERJ Open Research, 2020, 6, 00269-2020.	2.6	16
15	Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study. ERJ Open Research, 2020, 6, 00132-2020.	2.6	17
16	Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study. Journal of Cystic Fibrosis, 2020, 19, 931-933.	0.7	30
17	Building global development strategies for cf therapeutics during a transitional cftr modulator era. Journal of Cystic Fibrosis, 2020, 19, 677-687.	0.7	24
18	A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: Effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis, 2020, 19, 942-948.	0.7	15

#	Article	IF	Citations
19	Personalised medicine for non-classic cystic fibrosis resulting from rare CFTR mutations. European Respiratory Journal, 2020, 56, 2000062.	6.7	10
20	Dynamic perfluorinated gas MRI reveals abnormal ventilation despite normal FEV1 in cystic fibrosis. JCI Insight, 2020, 5, .	5.0	18
21	CFTR modulator theratyping: Current status, gaps and future directions. Journal of Cystic Fibrosis, 2019, 18, 22-34.	0.7	208
22	Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet, The, 2019, 394, 1940-1948.	13.7	804
23	Exercising our options: comparing effects of exercise and positive expiratory pressure on mucociliary clearance. European Respiratory Journal, 2019, 53, 1900510.	6.7	1
24	An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 171-180.	5.6	77
25	Critical Care of the Adult Patient With Cystic Fibrosis. Chest, 2019, 155, 202-214.	0.8	28
26	Beyond the expected: Identifying broad research priorities of researchers and the cystic fibrosis community. Journal of Cystic Fibrosis, 2019, 18, 375-377.	0.7	31
27	Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 526-528.	5.6	32
28	Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 650-656.	0.7	24
29	Homogeneity of Aerosol Deposition and Mucociliary Clearance are Improved Following Ivacaftor Treatment in Cystic Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 204-211.	1.4	5
30	Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 214-224.	5.6	152
31	Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. Journal of Cystic Fibrosis, 2018, 17, e13-e16.	0.7	52
32	SPLUNC1 degradation by the cystic fibrosis mucosal environment drives airway surface liquid dehydration. European Respiratory Journal, 2018, 52, 1800668.	6.7	28
33	Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR. JCI Insight, 2018, 3, .	5.0	56
34	Airways mucus pathogenesis in patients with non-cystic fibrosis bronchiectasis. , 2018, , .		4
35	Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. Journal of Cystic Fibrosis, 2017, 16, 371-379.	0.7	46
36	A Trans-Nasal Aerosol Delivery Device for Efficient Pulmonary Deposition. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2017, 30, 223-229.	1.4	11

#	Article	IF	Citations
37	Effects of inhaled high-molecular weight hyaluronan in inflammatory airway disease. Respiratory Research, 2016, 17, 123.	3.6	16
38	Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 386-391.	0.7	13
39	UDP-glucose promotes neutrophil recruitment in the lung. Purinergic Signalling, 2016, 12, 627-635.	2.2	47
40	Inhaled alpha 1 -proteinase inhibitor therapy in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 227-233.	0.7	43
41	Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic Fibrosis. Annals of the American Thoracic Society, 2016, 13 Suppl 2, S186-90.	3.2	2
42	Duration of action of hypertonic saline on mucociliary clearance in the normal lung. Journal of Applied Physiology, 2015, 118, 1483-1490.	2.5	39
43	CFTR Modulator Therapies for Cystic Fibrosis. Pediatric, Allergy, Immunology, and Pulmonology, 2015, 28, 230-236.	0.8	1
44	Heterogeneity of Particle Deposition by Pixel Analysis of 2D Gamma Scintigraphy Images. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 211-218.	1.4	13
45	Novel outcome measures for clinical trials in cystic fibrosis. Pediatric Pulmonology, 2015, 50, 302-315.	2.0	34
46	A Biophysical Basis for Mucus Solids Concentration as a Candidate Biomarker for Airways Disease. PLoS ONE, 2014, 9, e87681.	2.5	156
47	Hypertonic saline for cystic fibrosis: worth its salt?. Expert Review of Respiratory Medicine, 2014, 8, 267-269.	2.5	3
48	Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 175-184.	5.6	447
49	Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. Journal of Clinical Investigation, 2014, 124, 3047-3060.	8.2	272
50	New Pulmonary Therapies Directed at Targets Other than CFTR. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a009787-a009787.	6.2	15
51	Multisite Comparison of Mucociliary and Cough Clearance Measures Using Standardized Methods. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2013, 26, 157-164.	1.4	47
52	Comparison of ¹³³Xenon Ventilation Equilibrium Scan (XV) and ^{99m}Technetium Transmission (TT) Scan for Use in Regional Lung Analysis by 2D Gamma Scintigraphy in Healthy and Cystic Fibrosis Lungs. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2013, 26, 94-100.	1.4	19
53	Multicenter Intestinal Current Measurements in Rectal Biopsies from CF and Non-CF Subjects to Monitor CFTR Function. PLoS ONE, 2013, 8, e73905.	2.5	42
54	Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for theF508del-CFTRmutation. Thorax, 2012, 67, 12-18.	5.6	466

#	Article	IF	Citations
55	Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax, 2012, 67, 882-890.	5.6	60
56	Analysis of the Bacterial Communities Present in Lungs of Patients with Cystic Fibrosis from American and British Centers. Journal of Clinical Microbiology, 2011, 49, 281-291.	3.9	58
57	Cystic fibrosis lung disease starts in the small airways: Can we treat it more effectively?. Pediatric Pulmonology, 2010, 45, 107-117.	2.0	161
58	Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutation. New England Journal of Medicine, 2010, 363, 1991-2003.	27.0	741
59	SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11412-11417.	7.1	149
60	Hydrator therapies for cystic fibrosis lung disease. Pediatric Pulmonology, 2008, 43, S18-S23.	2.0	7
61	Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatric Pulmonology, 2008, 43, 1100-1106.	2.0	39
62	Extracellular purines are biomarkers of neutrophilic airway inflammation. European Respiratory Journal, 2008, 31, 949-956.	6.7	80
63	A2BAdenosine Receptors Regulate the Mucus Clearance Component of the Lung's Innate Defense System. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 190-197.	2.9	50
64	Sodium Channels and Cystic Fibrosis. Chest, 2007, 132, 1631-1636.	0.8	144
65	Mucociliary Clearance as an Outcome Measure for Cystic Fibrosis Clinical Research. Proceedings of the American Thoracic Society, 2007, 4, 399-405.	3.5	75
66	Rationale for Hypertonic Saline Therapy for Cystic Fibrosis Lung Disease. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 295-302.	2.1	37
67	Burkholderia gladioli: Five year experience in a cystic fibrosis and lung transplantation center. Journal of Cystic Fibrosis, 2007, 6, 267-273.	0.7	69
68	Mucus Clearance and Lung Function in Cystic Fibrosis with Hypertonic Saline. New England Journal of Medicine, 2006, 354, 241-250.	27.0	643
69	FisiopatologÃa de la fibrosis quÃstica. Annales NestlÃ© (Ed EspaÃ±ola), 2006, 64, 101-109.	0.1	1
70	Pathophysiology of Cystic Fibrosis. Annales Nestle, 2006, 64, 101-109.	0.1	6
71	Physiopathologie de la mucoviscidose. Annales Nestle [Ed Francaise], 2006, 64, 101-109.	0.0	2
72	Soluble Mediators, Not Cilia, Determine Airway Surface Liquid Volume in Normal and Cystic Fibrosis Superficial Airway Epithelia. Journal of General Physiology, 2006, 127, 591-604.	1.9	196

#	Article	IF	Citations
73	BURKHOLDERIA GLADIOLI: FIVE YEAR EXPERIENCE IN A CYSTIC FIBROSIS REFERRAL AND LUNG TRANSPLANTATION CENTER. Chest, 2005, 128, 152S.	0.8	1
74	Update on pathogenesis of cystic fibrosis lung disease. Current Opinion in Pulmonary Medicine, 2003, 9, 486-491.	2.6	125
75	Secreted and Cell-Associated Adenylate Kinase and Nucleoside Diphosphokinase Contribute to Extracellular Nucleotide Metabolism on Human Airway Surfaces. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 209-215.	2.9	60
76	Regulation of the Epithelial Sodium Channel by Serine Proteases in Human Airways. Journal of Biological Chemistry, 2002, 277, 8338-8345.	3.4	220
77	Basal Nucleotide Levels, Release, and Metabolism in Normal and Cystic Fibrosis Airways. Molecular Medicine, 2000, 6, 969-982.	4.4	79
78	Acute and Chronic Lung Allograft Rejection During Pregnancy. Chest, 1996, 110, 293-296.	0.8	25